Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 77,11 € (-4,68 %). La mediana es de 86,29 € (+6,66 %).
| Comprar |
9 |
| Mantener |
2 |
| Vender |
1 |
Debates en la comunidad
- 3M Spin-Off von Solventum
Gestern wurde der Spin-Off der Healthcare Sparte unter Solventum in den Depots durchgeführt. Man hat für jede vierte 3M Aktie eine Solventum Aktie erhalten. Komischerweise steht nun meine Position in…
Puncher I en Schnack
0 6 - Korrektur der automatisch erstellten Aktivität des Spin-Off´s bei 3M
Hallo zusammen, der Spin-Off von 3M wurde ja automatiasch in die Aktivitäten eingetragen. Hierzu mal ein dickes Lob für diese neue Funktion. Leider passt die nicht ganz bei mir - 3M bzw. Trade…
K Kai V en Schnack
0 14 - SpinOff 3M
Hallo, hier bei Parqet, ist ja der SpinOff schon eingetragen. Bei meinem Brocker Trade Republic ist dieser noch nicht abgeschlossen. Gibt es schon jemanden von euch, bei dem die Werte (Stückzahl,…
Maik S. II en Schnack 0 4 - Hallo, nach einem Spin-off bei 3M und A.P. Moller-Mearsk B werden mir falsche Einstiegskurse angezeigt. Ich kann das nicht korrigieren. Pflege ich die PDF Datei neu ein, kommen weiter Automatisch die falschen Einstiegskurse. Gibt es schon ein Lösung?
PN Parqet Nutzer IV en Schnack
1 27 - Neu: Automatische Buchung von Spin-Offs
Liebe Community, vielleicht haben die 3M Aktionäre von euch es schon im eigenen Depot entdeckt: Die automatische Buchung von Spin-Offs ist ab sofort live! Was bedeutet das für euch? Ab sofort werden…
Lisa I en Neues vom Parqet Team 37 51
Noticias Ir al feed de noticias
Solventum sharpens medtech strategy and plans spin-off of HIS division
Solventum announced at the Wells Fargo healthcare conference that it will focus more on medical technology and spin off its Healthcare Information Services (HIS) unit, with options including sale, spin-off or partnership. The company raised its forecast for organic growth in 2026 to 2.5–3.0% but expects a near-term margin dilution of around 400 basis points from the HIS separation. MedSurg and dental (over 80% of the business) remain the main growth drivers; about 20 new products are planned by Q1 2028, with a target of 4–5% organic growth for 2028 (ex-HIS). » Más en de.investing.com
Solventum reaches 52-week high at $88.21
Solventum shares rose to a new 52-week high of $88.21, gaining nearly 11% on the week. The health‑technology company has a market capitalization of $14.92 billion and is up about 20.6% year to date. Solventum beat expectations in Q1 of fiscal 2026 with EPS of $1.48 (forecast $1.34) on organic revenue growth of 2.1%. Analysts rated the stock positively; the P/E ratio is around 9.3, which the fair‑value estimate signals as a slight overvaluation. » Más en de.investing.com
UBS upgrade drives Solventum stock sharply higher
UBS upgraded Solventum from “Neutral” to “Buy” and set a $95 price target, implying roughly 18% upside. The stock rose 7.6% in morning trading and hit a daily high of $87.19, close to its 52-week high of $88.20. Earlier positive analyst notes from BTIG and KeyBanc, along with four consecutive quarters of EPS beats, underpin expectations for a strong Q2 report on Aug. 5. The rally was stock-specific while broad US indices were mostly weaker. » Más en de.investing.com
Trian demands cost cuts, divestments and buybacks at Solventum after spin-off
Trian Fund Management has disclosed just under a 5% stake in Solventum and, in an open letter, demanded three value-boosting measures: reduce overhead to 3M-levels, sell non-core divisions including Health Information Systems, and prioritize share buybacks. Trian criticizes that the market capitalization of around $12 billion is far below the $25 billion expected at the spin-off and sees about $13 billion of shareholder value destroyed. The investor also condemns high executive compensation since the spin-off without corresponding returns for shareholders and says it will communicate with other large shareholders and may adjust its position. » Más en de.investing.com
Trian demands cost cuts, sale of non-core businesses and share buybacks at Solventum
Trian Fund Management has disclosed an almost 5% stake in Solventum and, in an open letter, is calling for operational changes including reducing overhead to 3M levels, selling non-core divisions such as Health Information Systems, and prioritizing share buybacks. Trian criticizes Solventum for not delivering returns to shareholders since the spin-off and sees a dilution of company value compared with earlier analyst estimates. Solventum is trading near its 52-week low but remains profitable with earnings of $8.88 per share and a P/E ratio of 7.78. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 1720,68 M | 3,66 % |
| Beneficio bruto | 937,59 M | 6,52 % |
| Beneficio neto | -10,59 M | 100,98 % |
| EBITDA | 50,32 M | 96,57 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 13,75 mil M € |
Número de acciones | 169,96 M |
Máximo/mínimo de 52 semanas | 85,53 € - 56,66 € |
| Dividendos | No |
Beta | 0,75 |
Ratio P/E | 100,09 |
Ratio PEG | -1,11 |
Ratio P/B | 3,17 |
Ratio P/S | 1,85 |
Perfil de la empresa
Solventum Corporation, una empresa del sector sanitario, se dedica al desarrollo, la fabricación y la comercialización de una cartera de soluciones para atender necesidades críticas de clientes y pacientes. Opera a través de cuatro segmentos: Medsurg, Dental Solutions, Health Information Systems y Purification and Filtration. El segmento Medsurg ofrece soluciones que incluyen cuidado avanzado de heridas, gestión de sitios de I.V., garantía de esterilización, gestión de la temperatura, suministros quirúrgicos, estetoscopios y electrodos médicos. El segmento Dental Solutions proporciona un conjunto completo de productos dentales y de ortodoncia, incluidos brackets, alineadores, cementos restauradores y agentes de unión. Health Information Systems ofrece soluciones de software, incluidas herramientas asistidas por computadora, documentación médica, facturación directa y automatización de codificación, metodologías de clasificación, reconocimiento de voz y plataformas de visualización de datos. El segmento Purification and Filtration proporciona tecnologías de purificación y filtración, incluidos filtros, purificadores, cartuchos y membranas. La compañía fue constituida en 2023 y tiene su sede en Saint Paul, Minnesota.
| Nombre | Solventum |
| CEO | Bryan C. Hanson |
| Sede | Eagan,
mn Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 21/07/2014 |
| Empleados | 20.584 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | SOLV |
Frankfurt | KB7.F |
Düsseldorf | KB7.DU |
München | KB7.MU |